NicOx : Garufi ... e la Rivoluzione Pharma
- Creatore Discussione Yesod
- Data di Inizio
- Stato
doctor NO
NO nel DNA
NEWS du soir c'est Sanofi lire: Auj. à 18:13
Reuters le 30/01/2009 à 18:10 BREF- Sanofi - Le DG a annoncé des diversifications et des acquisitions - syndicat :
PARIS, 30 janvier (Reuters) - Un responsable syndical CGT de Sanofi-Aventis < SANOFI-AVENTIS > a déclaré vendredi que : * Le nouveau directeur général de Sanofi-Aventis < SANOFI-AVENTIS > Chris Viehbacher a annoncé aux salariés des diversifications de portefeuille et des acquisitions * Le nouveau DG veut renforcer le groupe en oncologie et développer trois ou quatre anticorps
* Un porte-parole de Sanofi a confirmé que le nouveau directeur général s'est
exprimé devant les salariés mais sans faire de commentaires sur le contenu.
Reuters le 30/01/2009 à 18:10 BREF- Sanofi - Le DG a annoncé des diversifications et des acquisitions - syndicat :
PARIS, 30 janvier (Reuters) - Un responsable syndical CGT de Sanofi-Aventis < SANOFI-AVENTIS > a déclaré vendredi que : * Le nouveau directeur général de Sanofi-Aventis < SANOFI-AVENTIS > Chris Viehbacher a annoncé aux salariés des diversifications de portefeuille et des acquisitions * Le nouveau DG veut renforcer le groupe en oncologie et développer trois ou quatre anticorps
* Un porte-parole de Sanofi a confirmé que le nouveau directeur général s'est
exprimé devant les salariés mais sans faire de commentaires sur le contenu.
doctor NO
NO nel DNA
forse stai sbagliando tipo di azione
la TI è un dinosauro in via di estinzione carico di debiti e che opera su un settore alla canna del gas e con una concorrenza alla massima potenza e con un classe dirigenziale a dir poco discutibile
nicox è un diamante ancora nella scatola ma quando luccicherà lo si vedrà ovunque
doctor NO
NO nel DNA
NEWS du soir c'est Sanofi lire: Auj. à 18:13
Reuters le 30/01/2009 à 18:10 BREF- Sanofi - Le DG a annoncé des diversifications et des acquisitions - syndicat :
PARIS, 30 janvier (Reuters) - Un responsable syndical CGT de Sanofi-Aventis < SANOFI-AVENTIS > a déclaré vendredi que : * Le nouveau directeur général de Sanofi-Aventis < SANOFI-AVENTIS > Chris Viehbacher a annoncé aux salariés des diversifications de portefeuille et des acquisitions * Le nouveau DG veut renforcer le groupe en oncologie et développer trois ou quatre anticorps
* Un porte-parole de Sanofi a confirmé que le nouveau directeur général s'est
exprimé devant les salariés mais sans faire de commentaires sur le contenu.
je crois que Sanofi est dans la partie
doctor NO
NO nel DNA
MARKETWATCH FIRST TAKE
Roche has more at risk than Genentech
Commentary: Swiss drug company's lowered bid poses its own challenges
By MarketWatch
Last update: 11:17 a.m. EST Jan. 30, 2009
LONDON (MarketWatch) -- Swiss drug manufacturer Roche is seeking to force a deal for the 44% of Genentech it doesn't already own, by putting a slightly lower bid of $86 a share directly to shareholders.
The move comes after six months of failed negotiations with a committee of Genentech's management following Roche's original bid of $89 a share. See related story on Roche's offer.
Roche (CH:ROG: news , chart , profile ) is betting that economic turmoil over the past six months has left Genentech (DNA: genentech inc com new
News , chart , profile , more
Last: 81.26-2.83-3.37%
12:28pm 01/30/2009
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
<IMG class=pixelTracking height=1 width=1 border=0>DNA 81.26, -2.83, -3.4%) shareholders anxious to raise cash from their stakes.
But the Swiss firm, or at least its management, runs a number of risks with the approach. One is that key talent at Genentech will leave if a hostile deal is completed. Another is that the valuation of a company in which Roche already holds a substantial interest will be diminished. And a third is that Roche's ability to raise the financing necessary to do a deal will be tested if a majority of the independent shareholders do accept its offer.
Those risks may be worthwhile to gain fuller control of Genentech's anti-cancer drugs as well as a pipeline that's expected to see four approvals from the FDA this year, alongside an additional 10 applications
come conferma l'articolo qua sopra OPA ostile Si ma non va in porto e quindi OPA se sarà amichevole con il giusto prezzo!!!!!!!!!!!!!
Roche has more at risk than Genentech
Commentary: Swiss drug company's lowered bid poses its own challenges
By MarketWatch
Last update: 11:17 a.m. EST Jan. 30, 2009
LONDON (MarketWatch) -- Swiss drug manufacturer Roche is seeking to force a deal for the 44% of Genentech it doesn't already own, by putting a slightly lower bid of $86 a share directly to shareholders.
The move comes after six months of failed negotiations with a committee of Genentech's management following Roche's original bid of $89 a share. See related story on Roche's offer.
Roche (CH:ROG: news , chart , profile ) is betting that economic turmoil over the past six months has left Genentech (DNA: genentech inc com new
News , chart , profile , more
Last: 81.26-2.83-3.37%
12:28pm 01/30/2009
Delayed quote data
Sponsored by:
<IMG class=pixelTracking height=1 width=1 border=0>DNA 81.26, -2.83, -3.4%) shareholders anxious to raise cash from their stakes.
But the Swiss firm, or at least its management, runs a number of risks with the approach. One is that key talent at Genentech will leave if a hostile deal is completed. Another is that the valuation of a company in which Roche already holds a substantial interest will be diminished. And a third is that Roche's ability to raise the financing necessary to do a deal will be tested if a majority of the independent shareholders do accept its offer.
Those risks may be worthwhile to gain fuller control of Genentech's anti-cancer drugs as well as a pipeline that's expected to see four approvals from the FDA this year, alongside an additional 10 applications
come conferma l'articolo qua sopra OPA ostile Si ma non va in porto e quindi OPA se sarà amichevole con il giusto prezzo!!!!!!!!!!!!!
doctor NO
NO nel DNA
e scucili sti euri tirchione
fai come il papero per pochi cents non le hai prese
DickSIM
Prima o poi....ci becco!
Netzach
Forumer storico
e scucili sti euri tirchionefai come il papero per pochi cents non le hai prese
Son mica qui a fare beneficenza ...
- Stato